Clinical features and prognostic factors of patients with chordoma in the spine: a retrospective analysis of 153 patients in a single center
- PMID: 25488908
- PMCID: PMC4482860
- DOI: 10.1093/neuonc/nou331
Clinical features and prognostic factors of patients with chordoma in the spine: a retrospective analysis of 153 patients in a single center
Abstract
Background: Chordoma in the spine is relatively rare, and minimal information has been published in the literature regarding this subject. Moreover, there are controversies over prognostic factors of this disease.
Methods: A retrospective analysis of chordoma in the spine was performed by survival analysis. Local relapse-free survival (LRFS) and overall survival (OS) were analyzed from the date of surgery to the date of local recurrence and death. The LRFS and OS rates were estimated using the Kaplan-Meier method to identify potential prognostic factors. Factors with P values ≤ .1 were subjected to multivariate analysis by Cox regression analysis. P values ≤ .05 were considered statistically significant.
Results: A total of 153 patients with spinal chordoma were included in the study. The mean follow-up period was 72.0 months (range, 1-279 months). Local recurrence was detected in 51 cases after initial surgery in our center, while death occurred in 42 cases. The statistical analysis suggested that tumor location of C3-L5, dedifferentiated chordoma, preoperative Frankel scores A-C, and total spondylectomy were independent prognostic factors for LRFS. In addition, total en bloc spondylectomy and Karnofsky' performance status (KPS) ≥ 80% were favorable factors for OS.
Conclusions: Total spondylectomy, by either en bloc or piecemeal method, could significantly reduce LRFS for spinal chordoma. Location of C3-L5 is a favorable factor for LRFS, while dedifferentiated subtype and preoperative Frankel scores A-C are adverse prognostic factors. In addition, total en bloc spondylectomy and KPS ≥ 80% significantly improve overall survival of patients with spinal chordoma.
Keywords: chordoma; prognostic factor; spine tumor; surgery; survival.
© The Author(s) 2014. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Figures
Comment in
-
The role of radiotherapy in the treatment of spinal chordomas: an integrative analysis of 523 cases.Neuro Oncol. 2015 Oct;17(10):1419-20. doi: 10.1093/neuonc/nov121. Neuro Oncol. 2015. PMID: 26395061 Free PMC article. No abstract available.
Similar articles
-
Prognostic factors of patients with spinal chondrosarcoma: a retrospective analysis of 98 consecutive patients in a single center.Ann Surg Oncol. 2014 Oct;21(11):3572-8. doi: 10.1245/s10434-014-3745-z. Epub 2014 May 16. Ann Surg Oncol. 2014. PMID: 24833099 Clinical Trial.
-
Chordoma of the mobile spine and sacrum: a retrospective analysis of a series of patients surgically treated at two referral centers.Ann Surg Oncol. 2010 Jan;17(1):211-9. doi: 10.1245/s10434-009-0740-x. Epub 2009 Oct 22. Ann Surg Oncol. 2010. PMID: 19847568
-
Factors affecting prognosis of patients with giant cell tumors of the mobile spine: retrospective analysis of 102 patients in a single center.Ann Surg Oncol. 2013 Mar;20(3):804-10. doi: 10.1245/s10434-012-2707-6. Epub 2012 Oct 25. Ann Surg Oncol. 2013. PMID: 23096699 Clinical Trial.
-
Prognostic Factors in Patients With Spinal Chordoma: An Integrative Analysis of 682 Patients.Neurosurgery. 2017 Nov 1;81(5):812-823. doi: 10.1093/neuros/nyx081. Neurosurgery. 2017. PMID: 28368502 Review.
-
[Chordoma].Neurochirurgie. 2014 Jun;60(3):63-140. doi: 10.1016/j.neuchi.2014.02.003. Epub 2014 May 23. Neurochirurgie. 2014. PMID: 24856008 Review. French.
Cited by
-
Chordoma: a systematic review of the epidemiology and clinical prognostic factors predicting progression-free and overall survival.Eur Spine J. 2018 Dec;27(12):3043-3058. doi: 10.1007/s00586-018-5764-0. Epub 2018 Sep 15. Eur Spine J. 2018. PMID: 30220042
-
Analysis of long-term outcome of image-guided volumetric modulated arc therapy (VMAT) for primary malignant tumor of the cervical spine.Cancer Biol Ther. 2020 Jul 2;21(7):623-628. doi: 10.1080/15384047.2020.1743149. Epub 2020 Apr 16. Cancer Biol Ther. 2020. PMID: 32298199 Free PMC article.
-
Molecular Targeted Therapy in the Treatment of Chordoma: A Systematic Review.Front Oncol. 2019 Feb 1;9:30. doi: 10.3389/fonc.2019.00030. eCollection 2019. Front Oncol. 2019. PMID: 30775316 Free PMC article.
-
Clinicopathological and Prognostic Characteristics in Dedifferentiated/Poorly Differentiated Chordomas: A Pooled Analysis of Individual Patient Data From 58 Studies and Comparison With Conventional Chordomas.Front Oncol. 2021 Aug 13;11:686565. doi: 10.3389/fonc.2021.686565. eCollection 2021. Front Oncol. 2021. PMID: 34490087 Free PMC article.
-
Treatment of dedifferentiated chordoma: a retrospective study from a large volume cancer center.J Neurooncol. 2019 Sep;144(2):369-376. doi: 10.1007/s11060-019-03239-3. Epub 2019 Jul 23. J Neurooncol. 2019. PMID: 31338785 Free PMC article.
References
-
- Healey JH, Lane JM. Chordoma: a critical review of diagnosis and treatment. Orthop Clin North Am. 1989;20(3):417–426. - PubMed
-
- McMaster ML, Goldstein AM, Bromley CM, et al. Chordoma: incidence and survival patterns in the United States, 1973–1995. Cancer Causes Control. 2001;12(1):1–11. - PubMed
-
- Casali PG, Stacchiotti S, Sangalli C, et al. Chordoma. Curr Opin Oncol. 2007;19(4):367–370. - PubMed
-
- Horten BC, Montague SR. In vitro characteristics of a sacrococcygeal chordoma maintained in tissue and organ culture systems. Acta Neuropathol. 1976;35(1):13–25. - PubMed
-
- Walcott BP, Nahed BV, Mohyeldin A, et al. Chordoma: current concepts, management, and future directions. Lancet Oncol. 2012;13(2):e69–e76. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous